Brief: GSK-Hansoh Osteosarcoma drug succeeds in Phase III studies
28/07/2026 12:33
BRIEF-GSK-Hansoh Osteosarcoma drug succeeds in Phase III studies July 28 (Reuters) - GSK plc GSK.L:
GSK PLC - HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ
GSK - ARTEMIS-011 PHASE III STUDY MEETS PRIMARY ENDPOINT IN RELAPSED OSTEOSARCOMA
GSK - RIS-REZ SHOWS SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL VERSUS CHEMOTHERAPY
GSK - NO NEW SAFETY SIGNALS IDENTIFIED IN ARTEMIS-011 STUDY
GSK - HANSOH PHARMA TO USE DATA FOR REGULATORY SUBMISSION IN CHINA
GSK: FOR RIS-REZ CONSISTENT BENEFIT WAS ALSO OBSERVED ACROSS SECONDARY ENDPOINTS, INCLUDING OVERALL SURVIVAL
Source text: ID:nRSb1879Oa
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))